Stay updated on Adjuvant Pembrolizumab in N2+ NSCLC Clinical Trial

Sign up to get notified when there's something new on the Adjuvant Pembrolizumab in N2+ NSCLC Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Adjuvant Pembrolizumab in N2+ NSCLC Clinical Trial page

  1. Check
    5 days ago
    Change Detected
    Summary
    Adds a literature citation for pembrolizumab in non-small-cell lung cancer (N Engl J Med. 2015;372:2018-2028) to provide background context for the drug's use in NSCLC.
    Difference
    0.1%
    Check dated 2026-06-19T22:09:26.000Z thumbnail image
  2. Check
    12 days ago
    Change Detected
    Summary
    The study record adds a named contact entry (Myung-Ju Ahn) and new help/navigation links (How to Read a Study Record, Common Questions, How to Join a Study), and adjusts the Intervention/Treatment label and related status wording.
    Difference
    1%
    Check dated 2026-06-12T16:30:21.000Z thumbnail image
  3. Check
    19 days ago
    Change Detected
    Summary
    The page now shows Revision: v3.5.5, replacing the previous Revision: v3.5.4. This indicates a recent editorial/system update to the page rather than a modification to study content.
    Difference
    0.1%
    Check dated 2026-06-05T12:18:37.000Z thumbnail image
  4. Check
    41 days ago
    Change Detected
    Summary
    The page's revision tag changed from v3.5.3 to v3.5.4, indicating a minor platform update. There is no evidence of changes to the study details or other content on the page.
    Difference
    0.1%
    Check dated 2026-05-15T03:14:37.000Z thumbnail image
  5. Check
    48 days ago
    Change Detected
    Summary
    A bibliographic citation was added referencing the 2012 NEJM article 'Safety and activity of anti-PD-L1 antibody in patients with advanced cancer.' This background reference situates the trial within the broader PD-L1 inhibitor literature.
    Difference
    0.1%
    Check dated 2026-05-07T23:13:02.000Z thumbnail image
  6. Check
    55 days ago
    Change Detected
    Summary
    Revision updated from v3.5.2 to v3.5.3, signaling a new release of the page content. This update represents a metadata/version change rather than substantive changes to the study details.
    Difference
    0.1%
    Check dated 2026-04-30T17:33:09.000Z thumbnail image

Stay in the know with updates to Adjuvant Pembrolizumab in N2+ NSCLC Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Adjuvant Pembrolizumab in N2+ NSCLC Clinical Trial page.